ผู้เขียน หัวข้อ: DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease  (อ่าน 17 ครั้ง)

habits

  • Jr. Member
  • **
  • กระทู้: 128
DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease
« เมื่อ: พฤษภาคม 08, 2021, 08:13:32 »
30 Aug 2020:  Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That’s the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020.1

The DAPA-CKD trial tested the hypothesis that treatment with dapagliflozin is superior to placebo in reducing the risk of renal and cardiovascular events in patients with chronic kidney disease (with or without type 2 diabetes) already receiving a stable dose of either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) as background therapy.คีโนออนไลน์


The primary composite endpoint was worsening kidney function (defined as >50% sustained decline in estimated glomerular filtration rate [eGFR] or onset of end-stage kidney disease), or death due to kidney disease or cardiovascular disease.

The secondary endpoints were, in hierarchical order: 1) a composite endpoint of worsening kidney function (defined as >50% sustained decline in eGFR or onset of end-stage kidney disease), or death from kidney failure; 2) a composite endpoint of hospitalisation for heart failure or cardiovascular death; and 3) all-cause mortality.